Opko Health Inc. (OPK) CEO Phillip Md Et Al Frost Acquires 10,000 Shares

Share on StockTwits

Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 10,000 shares of the business’s stock in a transaction on Monday, April 15th. The shares were purchased at an average price of $2.47 per share, with a total value of $24,700.00. Following the completion of the purchase, the chief executive officer now owns 3,068,951 shares in the company, valued at approximately $7,580,308.97. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Thursday, April 11th, Phillip Md Et Al Frost acquired 30,000 shares of Opko Health stock. The shares were purchased at an average price of $2.49 per share, with a total value of $74,700.00.
  • On Tuesday, April 9th, Phillip Md Et Al Frost acquired 10,000 shares of Opko Health stock. The shares were purchased at an average price of $2.51 per share, with a total value of $25,100.00.
  • On Thursday, April 4th, Phillip Md Et Al Frost acquired 20,000 shares of Opko Health stock. The shares were purchased at an average price of $2.53 per share, with a total value of $50,600.00.
  • On Monday, April 1st, Phillip Md Et Al Frost acquired 20,000 shares of Opko Health stock. The shares were purchased at an average price of $2.58 per share, with a total value of $51,600.00.
  • On Wednesday, March 27th, Phillip Md Et Al Frost acquired 100,000 shares of Opko Health stock. The shares were purchased at an average price of $2.49 per share, with a total value of $249,000.00.
  • On Monday, March 18th, Phillip Md Et Al Frost bought 40,000 shares of Opko Health stock. The shares were bought at an average price of $2.47 per share, for a total transaction of $98,800.00.
  • On Thursday, March 14th, Phillip Md Et Al Frost bought 250,000 shares of Opko Health stock. The shares were bought at an average price of $2.45 per share, for a total transaction of $612,500.00.
  • On Wednesday, March 6th, Phillip Md Et Al Frost bought 50,000 shares of Opko Health stock. The shares were bought at an average price of $2.57 per share, for a total transaction of $128,500.00.
  • On Thursday, February 28th, Phillip Md Et Al Frost bought 200,000 shares of Opko Health stock. The shares were bought at an average price of $2.48 per share, for a total transaction of $496,000.00.
  • On Wednesday, January 16th, Phillip Md Et Al Frost bought 10,000 shares of Opko Health stock. The shares were bought at an average price of $3.74 per share, for a total transaction of $37,400.00.

Shares of Opko Health stock opened at $2.47 on Wednesday. The company has a market cap of $1.51 billion, a PE ratio of -9.88 and a beta of 1.88. Opko Health Inc. has a 1-year low of $2.34 and a 1-year high of $6.40. The company has a debt-to-equity ratio of 0.03, a quick ratio of 0.96 and a current ratio of 1.10.

Opko Health (NASDAQ:OPK) last issued its earnings results on Wednesday, February 27th. The biotechnology company reported ($0.08) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.09) by $0.01. The business had revenue of $221.90 million for the quarter, compared to analysts’ expectations of $242.05 million. Opko Health had a negative return on equity of 7.69% and a negative net margin of 15.46%. As a group, analysts expect that Opko Health Inc. will post -0.2 earnings per share for the current fiscal year.

Several research analysts have recently weighed in on OPK shares. Zacks Investment Research cut Opko Health from a “hold” rating to a “sell” rating in a report on Friday, March 8th. ValuEngine upgraded Opko Health from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. Finally, Barrington Research restated a “buy” rating and set a $5.00 target price on shares of Opko Health in a report on Thursday, February 28th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $9.67.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. D. E. Shaw & Co. Inc. lifted its holdings in Opko Health by 20.5% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 24,165 shares of the biotechnology company’s stock valued at $73,000 after acquiring an additional 4,104 shares during the last quarter. Meeder Asset Management Inc. lifted its holdings in Opko Health by 58.7% in the first quarter. Meeder Asset Management Inc. now owns 13,102 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 4,846 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Opko Health by 36.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 23,049 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 6,097 shares during the last quarter. Legal & General Group Plc lifted its holdings in Opko Health by 5.8% in the fourth quarter. Legal & General Group Plc now owns 119,829 shares of the biotechnology company’s stock valued at $361,000 after acquiring an additional 6,540 shares during the last quarter. Finally, Diversified Trust Co acquired a new position in Opko Health in the fourth quarter valued at approximately $30,000. Hedge funds and other institutional investors own 23.10% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Opko Health Inc. (OPK) CEO Phillip Md Et Al Frost Acquires 10,000 Shares” was posted by Macon Daily and is the sole property of of Macon Daily. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this piece of content can be read at https://macondaily.com/2019/04/17/opko-health-inc-opk-ceo-phillip-md-et-al-frost-acquires-10000-shares.html.

Opko Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.

Read More: Day Trading – Risk Worth the Reward?

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.